Gated myocardial perfusion single photon emission computed tomography in the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial, Veterans Administration Cooperative study no. 424

Journal of Nuclear Cardiology

Volumn 13, Issue 5, 2006, Pages 685-698

  Shaw, Leslee J ^a   Heller, Gary V ^b   Casperson, Paul ^c   Miranda Peats, Romalisa ^a   Slomka, Piotr ^a   Friedman, John ^a   Hayes, Sean W ^a   Schwartz, Ronald ^d   Weintraub, William S ^e   Maron, David J ^f   Dada, Marcin ^b   King, Spencer ^g   Teo, Koon ^h   Hartigan, Pamela ⁱ   Boden, William E ^b,i   O'Rourke, Robert A ^c   Berman, Daniel S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARTFORD HOSPITAL   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e Christiana Medical Center

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^g PIEDMONT HOSPITAL   (United States)

^h MCMASTER UNIVERSITY   (Canada)

ⁱ VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

gated myocardial perfusion SPECT; prognosis; Randomized trial; secondary prevention

Indexed keywords

ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NITRATE; PRAVASTATIN; TECHNETIUM 99M; THALLIUM 201;

ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DRUG USE; EVIDENCE BASED MEDICINE; FREQUENCY ANALYSIS; GATED IMAGING; HEART CATHETERIZATION; HEART MUSCLE PERFUSION; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOMES RESEARCH; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK MANAGEMENT; SEQUENTIAL ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOMATOLOGY; VETERAN;

ALGORITHMS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; HUMANS; MYOCARDIUM; NEOVASCULARIZATION, PATHOLOGIC; PERFUSION; RISK FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME; VETERANS;

EID: 33748631863     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nuclcard.2006.06.134     Document Type: Article

References (61)

1. Klocke F.J., Baird M.G., Lorell B.H., Bateman T.M., Messer J.V., Berman D.S., et al., American College of Cardiology/American Heart Association/American Society for Nuclear Cardiology. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). Circulation 108 (2003) 1404-1418
2. Gibbons R.J., Abrams J., Chatterjee K., Daley J., Deedwania P.C., Douglas J.S., et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article. J Am Coll Cardiol 41 (2003) 159-168
3. Underwood S.R., Anagnostopoulos C., Cerqueira M., Ell P.J., Flint J., Harbinson M., et al. Myocardial perfusion scintigraphy: the evidence. A consensus conference organised by the British Cardiac Society, the British Nuclear Cardiology Society and the British Nuclear Medicine Society, endorsed by the Royal College of Physicians of London and the Royal College of Radiologists. Eur J Nucl Med Mol Imaging 31 (2004) 261-291
4. Miller D.D., Younis L.T., Bach R.G., Aguirre F., Wittry M.D., Goodgold H.M., et al. Correlation of pharmacological 99mtc-sestamibi myocardial perfusion imaging with poststenotic coronary flow reserve in patients with angiographically intermediate coronary artery stenoses. Circulation 89 (1994) 2150-2160
5. Shaw L.J., and Iskandrian A.E. Prognostic value of stress gated SPECT in patients with known or suspected coronary artery disease. J Nucl Cardiol 11 (2004) 171-185
6. Boden W.E., Weintraub W.S., O'Rourke R.A., Teo K.K., Hartigan P.M., Maron D.J., et al. Design and rationale of the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial. Veterans Affairs Cooperative Studies Program no. 424. Am Heart J 151 (2006) 1173-1179
7. Schaar J.A., Muller J.E., Falk E., Virmani R., Fuster V., Serruys P.W., et al. Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. Eur Heart J 25 (2004) 1077-1082
8. Califf R.M., Armstrong P.W., Carver J.R., D'Agostino R.B., and Strauss W.E. Stratification of patients into high, medium, and low risk subgroups for purposes of risk factor management. J Am Coll Cardiol 27 (1996) 964-1047
9. Hachamovitch R., Hayes S.W., Friedman J.D., Cohen I., and Berman D.S. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circ 107 (2003) 2900-2907
10. National Institute of Clinical Excellence. 2003/053 NICE issues updated guidance on the use of coronary artery stents for the treatment of coronary artery disease. Available at: http://www.nice.org.uk/page.aspx?o=90551; accessed on July 14, 2005.
11. Smith Jr. S.C., Dove J.T., Jacobs A.K., Kennedy J.W., Kereiakes D., Kern M.J., et al. American College of Cardiology; American Heart Association Task Force on Practice Guidelines. Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol 37 (2001) 2215-2239
12. Scanlon P.J., Faxon D.P., Audet A.M., Carabello B., Dehmer G.J., Eagle K.A., et al. ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol 33 (1999) 1756-1824
13. Dakik H.A., Kleiman N.S., Farmer J.A., He Z.X., Wendt J.A., Pratt C.M., et al. Intensive medical therapy versus coronary angioplasty for suppression of myocardial ischemia in survivors of acute myocardial infarction: a prospective, randomized pilot study. Circulation 98 (1998) 2017-2023
14. Parisi A.F., Hartigan P.M., and Folland E.D. Evaluation of exercise thallium scintigraphy versus exercise electrocardiography in predicting survival outcomes and morbid cardiac events in patients with single- and double-vessel disease. Findings from the Angioplasty Compared to Medicine (ACME) Study. J Am Coll Cardiol 30 (1997) 1256-1263
15. Kaltoft A., Bottcher M., Sand N.P., Nielsen T.T., and Rehling M. Electrocardiographic gated (99m)Tc-sestamibi SPECT immediately after primary percutaneous coronary intervention characterizes reperfusion success. Cardiology 99 (2003) 198-204
16. Lauer M.S., Lytle B., Pashkow F., Snader C.E., and Marwick T.H. Prediction of death and myocardial infarction by screening with exercise-thallium testing after coronary-artery-bypass grafting. Lancet 351 (1998) 615-622
17. Alazraki N.P., Krawczynska E.G., Kosinski A.S., DePuey E.G., Ziffer J.A., Taylor A.T., et al. Prognostic value of Tl-201 SPECT for patients with multivessel coronary disease post-revascularization: results from the Emory angioplasty-surgery trial. Am J Cardiol 84 (1999) 1369-1374
18. Zellweger M.J., Lewin H.C., Lai S., Dubois E.A., Friedman J.D., Germano G., et al. When to stress patients after coronary artery bypass surgery? Risk stratification in patients early and late post-CABG using stress myocardial perfusion SPECT: implications of appropriate clinical strategies. J Am Coll Cardiol 37 (2001) 144-152
19. Hecht H.S., Shaw R.E., Bruce T.R., Ryan C., Stertzer S.H., and Myler R.K. Usefulness of tomographic thallium-201 imaging for detection of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 66 (1990) 1314-1318
20. Hecht H.S., Shaw R.E., Chin H.L., Ryan C., Stertzer S.H., and Myler R.K. Silent ischemia after coronary angioplasty: evaluation of restenosis and extent of ischemia in asymptomatic patients by tomographic thallium-201 exercise imaging and comparison with symptomatic patients. J Am Coll Cardiol 17 (1991) 670-677
21. Pfisterer M., Rickenbacher P., Kiowski W., Muller-Brand J., and Burkart F. Silent ischemia after percutaneous transluminal coronary angioplasty: incidence and prognostic significance. J Am Coll Cardiol 22 (1993) 1446-1454
22. Milan E., Zoccarato O., Terzi A., Ettori F., Leonzi O., Niccoli L., et al. Technetium-99m-sestamibi SPECT to detect restenosis after successful percutaneous coronary angioplasty. J Nucl Med 37 (1996) 1300-1305
23. Breisblatt W.M., Barnes J.V., Weiland F., and Spaccavento L.J. Incomplete revascularization in multivessel percutaneous transluminal coronary angioplasty: the role for stress thallium-201 imaging. J Am Coll Cardiol 11 (1988) 1183-1190
24. Manyari D.E., Knudtson M., Kloiber R., and Roth D. Sequential thallium-201 myocardial perfusion studies after successful percutaneous transluminal coronary artery angioplasty: delayed resolution of exercise-induced scintigraphic abnormalities. Circulation 77 (1988) 86-95
25. Hirzel H.O., Nuesch K., Gruentzig A.R., and Luetolf U.M. Short- and long-term changes in myocardial perfusion after percutaneous transluminal coronary angioplasty assessed by thallium-201 exercise scintigraphy. Circulation 63 (1981) 1001-1007
26. Zhang X., Liu X., He Z.X., Shi R., Yang M., Gao R., et al. Long-term prognostic value of exercise 99mTc-MIBI SPET myocardial perfusion imaging in patients after percutaneous coronary intervention. Eur J Nucl Med Mol Imaging 31 (2004) 655-662
27. Zellweger M.J., Weinbacher M., Zutter A.W., Jeger R.V., Mueller-Brand J., Kaiser C., et al. Long-term outcome of patients with silent versus symptomatic ischemia six months after percutaneous coronary intervention and stenting. J Am Coll Cardiol 42 (2003) 33-40
28. Giedd K.N., and Bergmann S.R. Myocardial perfusion imaging following percutaneous coronary intervention: the importance of restenosis, disease progression, and directed reintervention. J Am Coll Cardiol 43 (2004) 328-336
29. Taylor A., Shaw L.J., Fayad Z., O'Leary D., Nissen S., Rader D., et al. Tracking atherosclerosis regression: a clinical tool in preventive cardiology. Atherosclerosis 180 (2005) 1-10
30. Raggi P., Taylor A., Fayad Z., O'Leary D., Nissen S., Rader D., et al. Atherosclerotic plaque imaging: contemporary role in preventive cardiology. Arch Int Med 165 (2005) 2345-2353
31. Dakik H.A., Alam S., and Timani N. Resolution of perfusion defects with anti-ischemic medical therapy. J Nucl Cardiol 7 (2000) 395-396
32. Harborne L., Fleming R., Lyall H., Norman J., and Sattar N. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet 361 (2003) 1894-1901
33. Ray K.K., and Cannon C.P. Pathological changes in acute coronary syndromes: the role of statin therapy in the modulation of inflammation, endothelial function and coagulation. J Thromb Thrombolysis 18 (2004) 89-101
34. Smith Jr. S.C., Blair S.N., Bonow R.O., Brass L.M., Cerqueira M.D., Dracup K., et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 104 (2001) 1577-1579
35. Modena M.G., Bonetti L., Coppi F., Bursi F., and Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 40 (2002) 505-510
36. Aoki M., Sakai K., Koyanagi S., Takeshita A., and Nakamura M. Effect of nitroglycerin on coronary collateral function during exercise evaluated by quantitative analysis of thallium-201 single photon emission computed tomography. Am Heart J 121 (1991) 1361-1366
37. Stegaru B., Loose R., Keller H., Buss J., and Wetzel E. Effects of long-term treatment with 120 mg of sustained-release isosorbide dinitrate and 60 mg of sustained-release nifedipine on myocardial perfusion. Am J Cardiol 61 (1988) 74-7E
38. Zacca N.M., Verani M.S., Chahine R.A., and Miller R.R. Effect of nifedipine on exercise-induced left ventricular dysfunction and myocardial hypoperfusion in stable angina. Am J Cardiol 50 (1982) 689-695
39. Sharir T., Rabinowitz B., and Chouraqui P. Anti-ischemic drugs reduce size of reversible defects in dipyridamole/submaximal exercise TI-201 SPECT imaging. J Nucl Cardiol 4 Suppl (1997) 71
40. Shehata A.R., Mascitelli V.A., Herman S.D., Ahlberg A.W., White M.P., Chen C., et al. Impact of acute propanolol administration on dobutamine-induced myocardial ischemia as evaluated by myocardial perfusion imaging and echocardiography. Am J Cardiol 80 (1997) 268-272
41. Cid E., and Mahmarian J.J. Factors affecting the diagnostic accuracy of quantitative single photon tomography combined with dobutamine stress. J Nucl Med 37 (1996) 58P
42. Patel A.D., and Iskandrian A.E. Role of single photon emission computed tomography imaging in the evaluation of therapy for angina pectoris. Am Heart J 145 (2003) 952-961
43. Lewin H.C., and Berman D.S. Achieving sustained improvement in myocardial perfusion: role of isosorbide mononitrate. Am J Cardiol 79 12B (1997) 31-35
44. Mahmarian J.J., Fenimore N.K., Marks G.F., Francis M.J., and Morales-Ballejo H. Transdermal nitroglycerin patch therapy reduces the extent of exercise-induced myocardial ischemia: results of a double-blind, placebo-controlled trial using quantitative thallium-201 tomography. J Am Coll Cardiol 24 (1994) 25-32
45. Zeiher A.M., Krause T., Schachinger V., Minners J., and Moser E. Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. Circulation 91 (1995) 2345-2352
46. Manfrini O., Pizzi C., Morgagni G., Fontana F., and Bugiardini R. Effect of pravastatin on myocardial perfusion after percutaneous transluminal coronary angioplasty. Am J Cardiol 93 (2004) 1391-1393
47. Hosokawa R., Nohara R., Linxue L., Tamaki S., Hashimoto T., Tanaka M., et al. Effect of long-term cholesterol-lowering treatment with HMG-CoA reductase inhibitor (simvastatin) on myocardial perfusion evaluated by thallium-201 single photon emission computed tomography. Jpn Circ J 64 (2000) 177-182
48. Yokoyama I., Ohtake T., Momomura S., Nishikawa J., and Sasaki Yomata M. Reduced coronary flow reserve in hypercholesterolemic patients without overt coronary stenosis. Circulation 94 (1996) 3232-3238
49. Blumenthal R.S., and Gluckman T.J. New insights into the relationship between myocardial perfusion and lipid-lowering. J Am Coll Cardiol 42 (2003) 611-613
50. Schwartz R.G. Beyond the cholesterol profile: monitoring therapeutic effectiveness of statin therapy. J Nucl Cardiol 8 (2001) 528-532
51. Eichstadt H.W., Abletshauser C.B., Stork T., and Weidinger G. Beneficial effects of fluvastatin on myocardial blood flow at two time-points in hypercholesterolemic patients with coronary artery disease. J Cardiovasc Pharmacol 35 (2000) 735-740
52. Schwartz R.G., Pearson T.A., Kalaria V.G., Mackin M.L., Williford D.J., Awasthi A., et al. Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastatin therapy: coronary artery disease regression single photon emission computed tomography monitoring trial. J Am Coll Cardiol 42 (2003) 600-610
53. Mostaza J.M., Gomez M.V., Gallardo F., Salazar M.L., Martin-Jadraque R., Plaza-Celemin L., et al. Cholesterol reduction improves myocardial perfusion abnormalities in patients with coronary artery disease and average cholesterol levels. J Am Coll Cardiol 35 (2000) 76-82
54. Gould K.L. Reversal of coronary atherosclerosis. Clinical promise as the basis for noninvasive management of coronary artery disease. Circulation 90 (1994) 1558-1571
55. O'Rourke R.A., Chaudhuri T., Shaw L., and Berman D.S. Resolution of stress-induced myocardial ischemia during aggressive medical therapy as demonstrated by single photon emission computed tomography imaging. Circulation 103 (2001) 2315
56. Gould K.L., Ornish D., Scherwitz L., Brown S., Edens R.P., Hess M.J., et al. Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. JAMA 274 (1995) 894-901
57. Mahmarian J.J., Shaw L.J., Olszewski G.H., Pounds B.K., Frias M.E., Pratt C.M., and INSPIRE investigators. Adenosine sestamibi SPECT post-infarction evaluation (INSPIRE) trial. J Nucl Cardiol 11 (2004) 458-469
58. Port SC. Imaging guidelines for nuclear cardiology procedures. Available at: http://www.asnc.org/imageuploads/g53-84imagingguidelines.pdf. Accessed June 16, 2006.
59. Berman D.S., Abidov A., Kang X., Hayes S.W., Friedman J.D., Sciammarella M.G., et al. Prognostic validation of a 17-segment score derived from a 20-segment score for myocardial perfusion SPECT interpretation. J Nucl Cardiol 11 (2004) 414-423
60. Therasse P., Arbuck S.G., Eisenhower E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J National Cancer Institute 92 (2000) 205-216
61. Berman D.S., Yang L., Slomka P., Miranda-Peats R., Hayes S.W., Gerlach J., et al. Interscan reproducibility of automated quantitative myocardial perfusion SPECT. [abstract]. J Nucl Med 47 (2006) 132P